...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical apheresis. >Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
【24h】

Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.

机译：针对活动性溃疡性结肠炎患者使用Cellsorba进行白细胞穿刺术的疗效和安全性的最佳血液穿刺术治疗量。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Leukocytapheresis (LCAP) is used as an adjunct therapy for patients with active ulcerative colitis (UC). Although, LCAP is routinely performed at 3,000 mL per session, we were interested to see that if this can be replaced with bodyweight (BW) adjusted volume. METHODS: In an open label prospective trial, the clinical response to BW adjusted LCAP (BWA-LCAP) was evaluated in 14 patients with active UC. Fourteen demography matched UC patients who had been treated with the routine 3,000 mL LCAP were randomly sampled from our database as a control group. All patients were given 10 weekly LCAP sessions. In the BWA-LCAP group, the processed blood volume (PBV) was set at 30 mL/kg x BW/session. Baseline demographic measures were not significantly different between the two groups. RESULTS: The average PBV in the BWA-LCAP group was 1971.0 +/- 330.0 mL, range 1,020-2,460. In both groups, the average UC clinical disease activity index, the endoscopic index, and the concomitant prednisolone dosage were significantly and equally reduced during the course of 10 LCAP. Accordingly, at the end of the trial, no significant difference was seen in any outcome measure between the two groups. However, a significantly higher incidence of adverse event (AE) was observed in the routine 3,000 mL LCAP group as compared with the BWA-LCAP group (P < 0.01). CONCLUSIONS: The outcomes of this investigation showed that the therapeutic efficacy of LCAP based on 30 mL/kg x BW is similar to the routine 3,000 mL per session LCAP. However, BWA-LCAP should be favored if one is to see the full potential of LCAP without AE.
机译：背景：白细胞去除术（LCAP）被用作活动性溃疡性结肠炎（UC）患者的辅助治疗。尽管LCAP通常每次使用3,000 mL，但我们有兴趣看到是否可以用体重（BW）调整后的体积代替。方法：在一项开放标签的前瞻性试验中，评估了14例活动性UC患者对BW调整的LCAP（BWA-LCAP）的临床反应。从我们的数据库中随机抽取14例经人口统计学匹配的UC患者，这些患者接受了常规3,000 mL LCAP的治疗，作为对照组。所有患者每周接受10次LCAP疗程。在BWA-LCAP组中，处理血量（PBV）设置为30 mL / kg x BW /疗程。两组之间的基线人口统计学指标无显着差异。结果：BWA-LCAP组的平均PBV为1971.0 +/- 330.0 mL，范围为1,020-2,460。在10个LCAP的过程中，两组的平均UC临床疾病活动指数，内窥镜指数和同时的泼尼松龙剂量均显着降低。因此，在试验结束时，两组之间在任何结局指标上均未见明显差异。然而，与BWA-LCAP组相比，常规3,000 mL LCAP组的不良事件（AE）发生率显着更高（P <0.01）。结论：这项研究的结果表明，以30 mL / kg x BW为基础的LCAP的治疗效果与常规每次3,000 mL LCAP相似。但是，如果要看到没有AE的LCAP的全部潜力，则应该偏爱BWA-LCAP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号